<DOC>
	<DOCNO>NCT01779921</DOCNO>
	<brief_summary>This study conduct globally . The aim study describe treatment modality outcomes bleed episode , surgery prophylaxis patient factor VII ( FVII ) deficiency addition evaluate presence ( already treat patient ) and/or appearance inhibiting antibody FVII and/or therapy-related thrombosis . Due Novo Nordisk commitment Committee Medicinal Products Human Use ( CHMP ) , Novo Nordisk receive data treatment activate recombinant human FVII ( rFVIIa , NovoSevenÂ® ) patient FVII deficiency Seven Treatment Evaluation Registry ( STER , NCT01269138 ) . These patient also treat haemostatics systemic administration .</brief_summary>
	<brief_title>Treatment Congenital Factor VII Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VII Deficiency</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>Signed informed consent patient next kin legally acceptable representative collect data treatment give bleed episode , surgical event prophylactic regimen specify protocol . If informed consent provide next kin legally acceptable representative , consent must also obtain patient soon he/she able . Informed consent preferentially obtain initiation treatment minimum entry data database Any patient FVII deficiency treatment bleed episode , prevention relate surgery primary/secondary prophylaxis consider necessary treat physician enrol Patients FVII deficiency without immediate need treatment enter stand register patient capture baseline demographic data . Admission data enter event occurs</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>